LENZING AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.92 EUR | +1.62% |
|
+0.15% | -8.44% |
| Jun. 28 | Lenzing CEO to Step Down March 2025; Successor Named | MT |
| Jun. 12 | Suzano to Buy 15% Stake in Lenzing from B&C Group | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Specialty Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.44% | 1.37B | - | ||
| +14.16% | 5.23B | C | ||
| -1.92% | 4.88B | C- | ||
| -29.08% | 2.61B | C | ||
| +10.78% | 2.33B | - | - | |
| +0.47% | 1.51B | B+ | ||
| -16.97% | 890M | - | D+ | |
| -15.58% | 848M | - | ||
| -5.86% | 583M | - | - | |
| -37.67% | 377M | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LNZ Stock
- 0NCV Stock
- Ratings Lenzing AG
